Tag: RET fusion NSCLC treatment

Home / RET fusion NSCLC treatment

Categories

Pralsetinib is approved by the FDA for non-small cell lung cancer with RET gene fusions

August 2023: Pralsetinib (Gavreto, Genentech, Inc.) was given regular approval by the Food and Drug Administration for adult patients with metastatic RET fusion-positive non-small cell lung cancer (N...
ret-fusion-nsclc-treatment

Scan the code